Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2013-04-17 Regulatory Filings
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Cyclopharm Develops New Nuclear Medicine Technology 4 pages 220.9KB
Regulatory Filings Classification · 95% confidence The document is a public announcement from Cyclopharm Limited dated 18 April 2013, describing the development of a new proprietary nuclear medicine technology called Ultralute. It includes statements from the Managing Director and Director of Science, background information about the company and its products, and details about the technology's potential benefits and upcoming presentations. The document is addressed to shareholders and includes a letter format. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or interim reports. The content focuses on a product development announcement and company update rather than financial results or governance changes. The document length is 7,912 characters, which is substantial but the content is clearly an announcement of a new technology and business development rather than a formal report or regulatory filing. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Investor Presentation.
2013-04-17 English
Notice of Annual General Meeting/Proxy Form 27 pages 120.3KB
AGM Information Classification · 100% confidence The document is titled 'Cyclopharm Limited Notice of Annual General Meeting and Explanatory Statement' and includes detailed information about the upcoming AGM, including the date, location, agenda items such as financial statements, remuneration report, re-election of director, share buy-back, and issue of shares to the managing director. It also contains proxy voting instructions and explanatory notes related to the AGM resolutions. The document is clearly a notice and explanatory statement for an Annual General Meeting, not the actual annual report or financial statements themselves. Therefore, it fits the category of AGM Information (AGM-R). The document length is substantial and contains detailed meeting information, consistent with an AGM notice and explanatory statement.
2013-04-14 English
Change of Director's Interest Notice 3 pages 116.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of securities held before and after the change, nature of the interest, and dates of changes. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades or director dealings. It is not an annual report, earnings release, or any other financial report but specifically a director's dealing notice. Therefore, the correct classification is 'DIRS' (Director's Dealing). The document length and content fully support this classification with high confidence.
2013-04-03 English
Form 484 - cancellation of Long Term Incentive Plan shares 2 pages 166.9KB
Regulatory Filings Classification · 90% confidence The document contains only references to omitted pictures and no textual content or financial data. It is extremely short (273 characters) and does not contain any report, announcement, or detailed information. Therefore, it cannot be classified as a substantive report or announcement. Given the lack of content, the best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2013-04-01 English
Annual Report to shareholders 93 pages 695.1KB
Annual Report Classification · 100% confidence The document is titled 'Cyclopharm Limited Annual Report 2012' and contains detailed financial highlights, chairman's letter, managing director's review, directors' report, auditor's independence declaration, corporate governance, comprehensive financial statements (income statement, balance sheet, cash flows, changes in equity), notes, director's declaration, independent audit report, and additional information. The content covers the full fiscal year ending 31 December 2012, with extensive financial data and management commentary. The length is substantial (15,000 characters), indicating a full report rather than a brief announcement. The presence of audited financial statements and comprehensive management discussion confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2012
2013-03-27 English
Change of Director's Interest Notice 3 pages 315.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the change (on-market trade), and related parties. There is no financial performance data, earnings information, or report content. The document is a formal notification of a director's personal share transactions, which fits the definition of Director's Dealing filings.
2013-03-25 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.